Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Contamination and Raw Material Testing Issues Raised in FDA Warning Letters

This article was originally published in The Gold Sheet

Executive Summary

FDA investigators are continuing to find contamination problems and inadequate testing, according to 20 warning letters issued in the first half of 2013, as well as a troubling trend of repeat observations at Baxter, Hospira and Apotex. Observers say to expect more sterility concerns in future warning letters, particularly involving mold, as FDA ramps up GMP enforcement at compounding pharmacies.

Advertisement

Related Content

FDA’s Blizzard of Enforcement at Compounding Pharmacies Evident in GMP Warning Letters for FY 2014
Drug Recalls Soared Again in 2013, Driven by Contamination
Empagliflozin Approval May Come This Year After Boehringer Resolves GMP Problems
Empagliflozin Approval May Come This Year After Boehringer Resolves GMP Problems
Drug Recalls Soared Again in 2013, Driven by Contamination
Contamination is Major Problem Seen in GMP Warning Letters
Contamination Issues Drove Drug Recalls to Record Levels in 2011
Another Busy Year of Drug Recalls Led to Shortages of Injectables
Poor Handling of Complaints, Contractors, Contamination Draw FDA Warning Letters
Record Drug Recall Totals for 2009 Resulted from GMP Breakdowns

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS000783

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel